You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Selten Pharma, LLC.
January 9, 2017
Selten Pharma And Vivus Announce Agreement For The Development And Commercialization Rights To Treatments For Pulmonary Arterial Hypertension (PAH)
June 10, 2016
Provides Updates on SPI-054 Development for the Treatment of Pulmonary Arterial Hypertension
BioCentury - Targeting BMPR2 signaling could give Selten first disease modifying therapy for Pulmonary Arterial Hypertension (PAH)
March 18, 2015
Selten Pharma Receives Orphan Drug Designation from U.S. FDA for the treatment of Pulmonary Arterial Hypertension (PAH)